AST

Battery Ventures Acquires GrammaTech’s Application Security Testing Software Business, Forming CodeSecure

Retrieved on: 
Tuesday, September 5, 2023
Data Management, Security, IOT (Internet of Things), Technology, Software, Networks, Intelligence, Defense, Internet of things, Canaccord Genuity, Research, Organization, Acquisition, McGuireWoods, Battery, Growth, Statista, CodeSonar, Battery Ventures, AST, Safety, Financial services, Risk management, DevOps, GrammaTech

GrammaTech , a high-profile provider of application security testing products and software research services, today announced that Battery Ventures has acquired its software products division, including the CodeSonar and CodeSentry product lines.

Key Points: 
  • GrammaTech , a high-profile provider of application security testing products and software research services, today announced that Battery Ventures has acquired its software products division, including the CodeSonar and CodeSentry product lines.
  • The transaction establishes a new, independent entity that will operate under the CodeSecure, Inc. name and be headquartered in Bethesda, Maryland.
  • GrammaTech will continue to offer cyber security research and development services and tools to the US defense and intelligence community.
  • More organizations are buying this software as the number of attacks on software supply chains increases, prompting them to build security into their software-development lifecycles earlier.

Storage Summit 2023: A Confluence of Tech Titans in Cape Breton Island, August 24-26

Retrieved on: 
Tuesday, August 22, 2023
Beer, EST, PST, RSVP, Bras, AST, BST, Tourism, Proxmox

SYDNEY, Nova Scotia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - 45Drives, the leader in on-premise data storage for New Enterprise, proudly announces the highly-anticipated first annual Storage Summit 2023, August 24-26 on Cape Breton Island, Nova Scotia.

Key Points: 
  • SYDNEY, Nova Scotia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - 45Drives, the leader in on-premise data storage for New Enterprise, proudly announces the highly-anticipated first annual Storage Summit 2023, August 24-26 on Cape Breton Island, Nova Scotia.
  • This summit promises an unmissable opportunity for enthusiasts, professionals, and tech aficionados to dive into the past, present, and future of data storage and its seamless integration within the IT landscape.
  • He continued, "Storage Summit 2023 is not just a conference; it's a celebration of knowledge-sharing and a platform to propel the future of data storage into uncharted territories.
  • Cape Breton Island's breathtaking landscapes provide an idyllic backdrop for this unique event, with the sailboat excursion offering an innovative and invigorating twist to the traditional tech conference experience.

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 15, 2023
Drug development, NASH, Hepatocellular carcinoma, Liver disease, GGT, COVID-19, Food and Drug Administration, Cancer, Cirrhosis, FVC, Cough, LOXL2, Model for End-Stage Liver Disease, Fibrosis, Vital capacity, Patient, Investment, Periodic breathing, ALT, Mortality, FDA, IPF, Death, AST, Idiopathic pulmonary fibrosis, Food, Safety, Pharmaceutical industry, Medical device, Medicine, MELD, Hepatology, Galecto Biotech

Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.

Key Points: 
  • Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.
  • “We are very disappointed that the GALACTIC-1 results do not support the continued development of GB0139 as a new treatment for IPF,” said Hans Schambye, President and Chief Executive Officer of Galecto.
  • The trial compared treatment with the inhaled 3 mg dose of GB0139 to placebo (randomized 2:1) over 52 weeks.
  • Galecto previously announced topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, its orally available galectin-3 inhibitor, for the treatment of decompensated cirrhosis.

AST SpaceMobile Provides Second Quarter 2023 Business Update

Retrieved on: 
Monday, August 14, 2023
Telecommunications, Satellite, Public Relations, Investor Relations, Communications, Technology, Aerospace, Manufacturing, Mobile, Wireless, AT&T, Senior, Table, Bluebird, Eastern Time Zone, Line of credit, GAAP, Research, History, ATM, Data-rate units, ASTS, Webcast, Vodafone, Depreciation, AST, Mobile phone, Security (finance), Cryptocurrency, Television, AST SpaceMobile

AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by standard mobile phones, is providing its business update for the second quarter ended June 30, 2023.

Key Points: 
  • AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by standard mobile phones, is providing its business update for the second quarter ended June 30, 2023.
  • This quarter we achieved space-based 4G LTE cellular broadband capabilities to everyday smartphones, reaching speeds above 10 Mbps during BlueWalker 3 testing alongside AT&T, Vodafone and Nokia,” said Abel Avellan, Chairman and Chief Executive Officer of AST SpaceMobile.
  • AST SpaceMobile will hold a quarterly business update conference call at 5:00 p.m. (Eastern Time) on Monday, August 14, 2023.
  • The call will be accessible via a live webcast on the Events page of AST SpaceMobile’s Investor Relations website at https://ast-science.com/investors/ .

Atlas Credit Partners Provides $100 Million Strategic Financing to AST SpaceMobile

Retrieved on: 
Tuesday, August 15, 2023
AT&T, Atlas, AST SpaceMobile, American Tower, Partnership, AST, AT, ACP, ASTS, Airline, Vodafone

HOUSTON, Aug. 15, 2023 /PRNewswire/ -- Atlas Credit Partners ("ACP"), an asset management firm specializing in investing and partnering with businesses on a direct basis, today announced a $100 million strategic financing to AST SpaceMobile, Inc. ("AST") (NASDAQ: ASTS), with approximately $50 million funded at closing.

Key Points: 
  • HOUSTON, Aug. 15, 2023 /PRNewswire/ -- Atlas Credit Partners ("ACP"), an asset management firm specializing in investing and partnering with businesses on a direct basis, today announced a $100 million strategic financing to AST SpaceMobile, Inc. ("AST") (NASDAQ: ASTS), with approximately $50 million funded at closing.
  • The ACP credit facility will provide AST with additional resources to continue building a globally connected satellite-based cellular broadband network directly accessible by standard mobile phones.
  • "Atlas Credit Partners' financial commitment to us is an important part of our comprehensive financing plan."
  • It's a privilege to invest alongside so many global industry leaders and further position AST for long-term success," said Drew Mallozzi, Chief Investment Officer and Managing Partner at Atlas Credit Partners.

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Total, KCR, European Renal Association, Autoimmune hepatitis, Week, Cohort, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, National Kidney Foundation, ALT, KZR, EULAR, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Vaccine, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • The complete MISSION Phase 1b/2 results were presented as an oral presentation at the LUPUS & KCR 2023 meeting, which took place May 17-20, 2023 in Seoul, Korea.
  • Research and development expenses for the second quarter of 2023 increased by $9.7 million to $21.0 million compared to $11.3 million in the second quarter of 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 increased by $0.8 million to $5.8 million compared to $5.0 million in the second quarter of 2022.

Synopsys Partners with NowSecure and Secure Code Warrior to Expand Industry-Leading Application Security Testing Solutions Portfolio

Retrieved on: 
Tuesday, August 8, 2023
SDLC, Learning, DevOps, Partnership, Developer, ASPM, API, MAST, Android, Software, Privacy, IOS, Security, Mobile, Organization, SNPS, Business Integration Group, Inc., Android SDK, Ides, NowSecure, AI, Maritime Civil Affairs and Security Training Command, AST, Online shopping, Medical device, Risk management, Synopsys

SUNNYVALE, Calif., Aug. 8, 2023 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS) today announced the details around two new collaboration agreements with NowSecure, recognized experts in mobile security and privacy, and Secure Code Warrior, provider of the leading agile learning platform for developer-driven security, to expand its Software Integrity Group's industry-leading portfolio of application security testing (AST) solutions.  

Key Points: 
  • Agreements Provide Enterprises with Enhanced Mobile Application Security Testing Capabilities, Access to Thousands of Agile Secure Code Learning Experiences for Developers
    SUNNYVALE, Calif., Aug. 8, 2023 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS ) today announced the details around two new collaboration agreements with NowSecure , recognized experts in mobile security and privacy, and Secure Code Warrior , provider of the leading agile learning platform for developer-driven security, to expand its Software Integrity Group's industry-leading portfolio of application security testing (AST) solutions.
  • Synopsys is introducing two new application security solutions leveraging these strategic partners: Synopsys Mobile Application Security Testing powered by NowSecure and Synopsys Developer Security Training powered by Secure Code Warrior.
  • "The NowSecure automated mobile capabilities seamlessly complement Synopsys' industry-leading managed services in mobile application security testing to provide an unparalleled level of coverage and scalability.
  • For more information about Mobile Application Security Testing, visit the Synopsys website and read today's detailed blog post .

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Retrieved on: 
Monday, August 7, 2023
Exercise, IRC, Hypophosphatemia, Human, Arm, DOR, Clinical trial, NDA, MAPK, MEK, CPK, CSR, ASCO, Vomiting, Wild Arms 2, Independent Review Committee, Patient, Investment, Maculopapular rash, Anemia, Ageing, FDA, Headache, Research, AST, Society, Conference, Safety, Fatigue, D, Pharmaceutical industry, Nursing, Cryptocurrency, Pediatrics

BRISBANE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its second quarter 2023 financial results and highlighted recent corporate achievements.

Key Points: 
  • R&D Expenses: Research and development expenses were $32.2 million for the second quarter of 2023 compared to $22.6 million for the second quarter of 2022.
  • G&A Expenses: General and administrative expenses were $17.1 million for the second quarter of 2023 compared to $14.2 million for the second quarter of 2022.
  • Net Loss: Net loss totaled $45.9 million for the second quarter of 2023 with non-cash stock compensation expense of $9.5 million, compared to $36.5 million for the second quarter of 2022 with non-cash stock compensation expense of $5.6 million.
  • 2023 Wedbush PacGrow Healthcare Conference, August 8-9, 2023
    Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023

Contrast Security Releases Assess Feature for LLMs to Protect Against AI Security Threats

Retrieved on: 
Thursday, August 3, 2023
LLM, API, OWASP, OpenAI, Wilson, Application security, Application, Risk, LOS, AI, AST, Organization, Online shopping, Medical device, Contrast, Python

LOS ALTOS, Calif., Aug. 3, 2023 /PRNewswire/ -- Contrast Security (Contrast), the code security platform built for developers and trusted by security, today announced it will extend its market-leading application security testing (AST) platform to support testing of Large Language Models (LLMs) from OpenAI. In this first release, Contrast rules help teams that are developing software using the OpenAI application programming interface (API) set to identify and mitigate weaknesses that could expose an organization to prompt injection vulnerabilities: i.e., attacks involving injection of a prompt that deceives the application into executing unauthorized code.

Key Points: 
  • Contrast is the first security solution to respond to this new industry standard list by delivering this capability.
  • "As project lead for the new OWASP Top 10 for LLMs, I can say our group looked deeply at many attack vectors against LLMs.
  • Contrast is ideal for identifying all types of injection accurately, including this new form of AI prompt injection.
  • To learn more about how Contrast Assess provides the first security solution created to identify potential prompt injection vulnerabilities, please visit our website or schedule a demo .

STERIS Announces Financial Results for Fiscal 2024 First Quarter

Retrieved on: 
Tuesday, August 1, 2023
STE, Health care, Sterilization, Customer, Transaction, Steris, BD (company), AST, BDX, NYSE, Dental, Security (finance), Video game

Revenue as reported for the quarter increased 11% to $1.28 billion compared with $1.16 billion in the first quarter of fiscal 2023.

Key Points: 
  • Revenue as reported for the quarter increased 11% to $1.28 billion compared with $1.16 billion in the first quarter of fiscal 2023.
  • Constant currency organic revenue (see Non-GAAP Financial Measures) also increased 11% for the first quarter of fiscal 2024 as compared to the first quarter of fiscal 2023.
  • Healthcare revenue as reported grew 17% in the quarter to $818.9 million compared with $698.5 million in the first quarter of fiscal 2023.
  • Operating income improved to $22.0 million in the first quarter of fiscal 2024 compared with $19.6 million in the prior year’s first quarter.